The molecular mechanism underlying
microRNA (miR)-17 overexpression has not been clearly evaluated in
gastric cancer. We aimed to evaluate the functional roles of miR-17 in
gastric cancer and test its viability as a therapeutic target. We conducted comparative genomic hybridization and expression array analyses on human
gastric cancer tissue samples, as well as evaluating the functional roles of miR-17 in
gastric cancer cell lines and transgenic mice. miR-17 overexpression in
gastric cancer patients was associated with copy number gain of proliferation-associated oncogenes such as MYC, CCNE1, ERBB2, and FGFR2. Copy number gain of MIR17HG gene (13q31.3) was rare, with an overall frequency of 2% in
gastric cancers (1 of 51). miR-17 knockdown suppressed the monolayer and anchorage-independent growth of FGFR2-amplified KATO-III
gastric cancer cells. mir-17-92 TG/TG mice overexpressing the mir-17-92 cluster under the
villin promoter developed spontaneous benign
tumors in the intestinal tract (log-rank P for
tumor-free survival = 0.069). Taken together, miR-17 overexpression in
gastric cancer was rarely associated with MIR17HG gene amplification, but correlated with proliferation-associated oncogene amplification. Therefore, miR-17-targeting approach may benefit patients with
gastric cancers harboring proliferation-associated oncogene amplification.